Prognostic and predictive roles of KRAS mutation in colorectal cancer

Amanda K. Arrington; Eileen L. Heinrich; Wendy Lee; Marjun Duldulao; Supriya Patel; Julian Sanchez; Julio Garcia-Aguilar; Joseph Kim

doi:10.3390/ijms131012153

Prognostic and predictive roles of KRAS mutation in colorectal cancer

Amanda K. Arrington, Eileen L. Heinrich, Wendy Lee, Marjun Duldulao, Supriya Patel, Julian Sanchez, Julio Garcia-Aguilar, Joseph Kim

Research output: Contribution to journal › Review article › peer-review

161 Scopus citations

Abstract

The RAS gene family is among the most studied and best characterized of the known cancer-related genes. Of the three human ras isoforms, KRAS is the most frequently altered gene, with mutations occurring in 17%-25% of all cancers. In particular, approximately 30%-40% of colon cancers harbor a KRAS mutation. KRAS mutations in colon cancers have been associated with poorer survival and increased tumor aggressiveness. Additionally, KRAS mutations in colorectal cancer lead to resistance to select treatment strategies. In this review we examine the history of KRAS, its prognostic value in patients with colorectal cancer, and evidence supporting its predictive value in determining appropriate therapies for patients with colorectal cancer.

Original language	English (US)
Pages (from-to)	12153-12168
Number of pages	16
Journal	International journal of molecular sciences
Volume	13
Issue number	10
DOIs	https://doi.org/10.3390/ijms131012153
State	Published - Oct 2012

Keywords

Colon cancer
Colorectal cancer
EGFR
KRAS
Let7
Oncogenes
Ras

ASJC Scopus subject areas

Catalysis
Molecular Biology
Spectroscopy
Computer Science Applications
Physical and Theoretical Chemistry
Organic Chemistry
Inorganic Chemistry

Access to Document

10.3390/ijms131012153

Cite this

@article{4b0e8c706c98456d8be544bfbd13d62a,

title = "Prognostic and predictive roles of KRAS mutation in colorectal cancer",

abstract = "The RAS gene family is among the most studied and best characterized of the known cancer-related genes. Of the three human ras isoforms, KRAS is the most frequently altered gene, with mutations occurring in 17%-25% of all cancers. In particular, approximately 30%-40% of colon cancers harbor a KRAS mutation. KRAS mutations in colon cancers have been associated with poorer survival and increased tumor aggressiveness. Additionally, KRAS mutations in colorectal cancer lead to resistance to select treatment strategies. In this review we examine the history of KRAS, its prognostic value in patients with colorectal cancer, and evidence supporting its predictive value in determining appropriate therapies for patients with colorectal cancer.",

keywords = "Colon cancer, Colorectal cancer, EGFR, KRAS, Let7, Oncogenes, Ras",

author = "Arrington, {Amanda K.} and Heinrich, {Eileen L.} and Wendy Lee and Marjun Duldulao and Supriya Patel and Julian Sanchez and Julio Garcia-Aguilar and Joseph Kim",

year = "2012",

month = oct,

doi = "10.3390/ijms131012153",

language = "English (US)",

volume = "13",

pages = "12153--12168",

journal = "International journal of molecular sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "10",

}

TY - JOUR

T1 - Prognostic and predictive roles of KRAS mutation in colorectal cancer

AU - Arrington, Amanda K.

AU - Heinrich, Eileen L.

AU - Lee, Wendy

AU - Duldulao, Marjun

AU - Patel, Supriya

AU - Sanchez, Julian

AU - Garcia-Aguilar, Julio

AU - Kim, Joseph

PY - 2012/10

Y1 - 2012/10

N2 - The RAS gene family is among the most studied and best characterized of the known cancer-related genes. Of the three human ras isoforms, KRAS is the most frequently altered gene, with mutations occurring in 17%-25% of all cancers. In particular, approximately 30%-40% of colon cancers harbor a KRAS mutation. KRAS mutations in colon cancers have been associated with poorer survival and increased tumor aggressiveness. Additionally, KRAS mutations in colorectal cancer lead to resistance to select treatment strategies. In this review we examine the history of KRAS, its prognostic value in patients with colorectal cancer, and evidence supporting its predictive value in determining appropriate therapies for patients with colorectal cancer.

AB - The RAS gene family is among the most studied and best characterized of the known cancer-related genes. Of the three human ras isoforms, KRAS is the most frequently altered gene, with mutations occurring in 17%-25% of all cancers. In particular, approximately 30%-40% of colon cancers harbor a KRAS mutation. KRAS mutations in colon cancers have been associated with poorer survival and increased tumor aggressiveness. Additionally, KRAS mutations in colorectal cancer lead to resistance to select treatment strategies. In this review we examine the history of KRAS, its prognostic value in patients with colorectal cancer, and evidence supporting its predictive value in determining appropriate therapies for patients with colorectal cancer.

KW - Colon cancer

KW - Colorectal cancer

KW - EGFR

KW - KRAS

KW - Let7

KW - Oncogenes

KW - Ras

UR - http://www.scopus.com/inward/record.url?scp=84867762949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867762949&partnerID=8YFLogxK

U2 - 10.3390/ijms131012153

DO - 10.3390/ijms131012153

M3 - Review article

C2 - 23202889

AN - SCOPUS:84867762949

SN - 1661-6596

VL - 13

SP - 12153

EP - 12168

JO - International journal of molecular sciences

JF - International journal of molecular sciences

IS - 10

ER -

Prognostic and predictive roles of KRAS mutation in colorectal cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this